URGNUroGen Pharma Ltd.

$918M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+228.0% YoY

Gross Profit

$10M89.0% margin

Operating Income

-$23M-206.5% margin

Net Income

-$30M-266.2% margin

EPS (Diluted)

$-1.35

QoQ Revenue Growth

-12.9%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$135M

Total Liabilities

$103M

Stockholders' Equity

$32M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$3M	+228.0%
Gross Profit	$10M	$3M	+220.7%
Operating Income	-$23M	-$29M	+19.5%
Net Income	-$30M	-$29M	-4.8%

Revenue Segments

Jelmyto

$11M100%

URGN Q3 2021 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena